

# Index

## A

- accelerated preservative testing, 28
- acid tolerance in microorganisms, 11
- acne, 225–229
  - microorganisms, 24–25
- AD (atopic dermatitis), 229–230
  - hygiene hypotheses, 253
  - oral probiotics, 253–254
  - SCORAD (scoring atopic dermatitis), 253
- adenosine triphosphate (ATPases), 11
- aerobic plate counts (APCs), 2
- antidandruff products, 223–225
  - microorganisms, 24
- APCs (aerobic plate counts), 2
- APs (antiperspirants), 24
- atopic dermatitis. *See* AD
- ATPases (adenosine triphosphate), 11
- atypical product preservation, 99–104, 293–294

## B

- BACTEC and BacT/Alert, 319
- bacteria growth curve, 2–5
- biofilms, 11–12, 269–270, 275
- biotherapeutic agents *versus* probiotics, 241
- BP (British Pharmacopeia), testing
  - acceptance criteria, 69
- bracketing techniques, 21, 182–183, 302
- British Pharmacopeia, testing acceptance criteria, 69

## C

- California Certified Organic Farmers (CCOF), 159
- capsules/glycocalyx, 11–12
- cell envelope, 9–10
- cell wall, 9–10
- CGMPs (current good manufacturing practices), 17, 167

- equipment/plant sanitation and maintenance, 21–22, 170, 183–184, 196–198, 277–278, 300–301, 303–305
- implementation, 169–173
- personnel, responsibilities and training, 169–170, 304
- quality controls, 169
  - laboratories, 172–173
  - microbial contamination, 171–172
  - production/processes, 170–171
- sampling and testing during production, 171
- Clostridium difficile*, 246
- CNS (coagulase-negative staphylococci), 211–216
  - underarm odor, 221–223
- COLIPA (European Cosmetic Toiletry and Perfumery Association), microbiological testing, 230
- colonization resistance by microorganisms, 211
- contract manufacturers, guidelines, 206–207
- coryneform bacteria, 217–218
- underarm odor, 221–223
- Cosmetic, Toiletry, and Fragrance Association (CTFA). *See* PCPC
- cosmetic microbiology
  - history, 17–18
  - manufacturing
    - quality controls, 22–23, 169–173
    - safety, 22–23
    - sanitation of plants and equipment, 20–22, 170–172, 183–184, 300–301, 303–305
    - testing process, 18–20
- outlook
  - globalization of testing, 320–321
  - impedance testing, 318–319
  - microbial detection systems, 319–320
  - organic and natural products, 323

- preservative efficacy testing, 315–317
- preservatives and antibiotics, cross-resistance, 312–315
- probiotics, 324–325
- product release testing, 317–318
- product development, 18–20
- skin conditions, 24–25
- Council of Europe, manufacturing guidelines, 168
- CTFA (Cosmetic, Toiletry, and Fragrance Association). *See* PCPC
- current good manufacturing practices. *See* CGMPs

## D

- dandruff, 223–225
  - microorganisms, 24
- DC (dendritic cells), 248–249
- deodorants
  - CNS (coagulase-negative staphylococci), 211–216
    - underarm odor, 221–223
  - microorganisms, 24
- dermatophytoses (fungal infections), 230–233
- dextran (glucose polymer), 11–12
- diarrhea treatments, 246–247
- diphtheroid, 217
- disaccharide lactulose, 256
- dry product preservation, 294–295
- D-values, 32–40

## E

- E. coli* infection treatments, 250
- EDTA (ethylenediaminetetraacetic acid), 134–135
- EHEC (enterohemorrhagic *E. coli*), 250
- enteropathogenic *E. coli* (EPEC), 250
- enzymes, preservative-free products, 157–158
- EP (European Pharmacopeia), preservative efficacy testing, 28
  - acceptance criteria, 47
- EPEC (enteropathogenic *E. coli*), 250
- Epidermophyton*, 230–233

- EPSs (exopolysaccharides), 11–12, 268–269, 275
- equipment in manufacturing
  - CGMPs, 20–22, 170
  - sanitation practices/training, 183–184, 196–198, 277–278, 300–301, 303–305
- ETA (exotoxin A), 272
- ethylenediaminetetraacetic acid (EDTA), 134–135
- ETS (exotoxin S), 272
- European Cosmetic Toiletry and Perfumery Association (COLIPA), 230
- European Pharmacopeia. *See* EP
- exopolysaccharides (EPSs), 11–12, 268–269, 275

## F

- FAO (Food and Agriculture Organization), probiotics, 241
- FDA (Food and Drug Administration)
  - CGMPs (current good manufacturing practices), 167
  - Cosmetic Good Manufacturing Practice Guidelines update, 173–174
  - cosmetic microbiology, 17
  - globalization of microbiological testing, 320
- FD&C Act (Food, Drug & Cosmetic Act), CGMPs, 169
- finished product testing. *See* product release testing
- flagella, 272
- flow cytometry, 319
- Food, Drug, and Cosmetic Act, 17
- Food and Agriculture Organization (FAO), probiotics, 241
- Food and Drug Administration. *See* FDA
- FOS (fructooligosaccharides), 256
- fungal infections (dermatophytoses), 230–233

## G

- galactooligosaccharides, 256
- GALT (gut-associated lymphoid tissue), 242, 249
- gastric ulcer treatments, 247

- gastrointestinal tract and probiotics  
 cross talk between probiotic bacteria  
 and cells, 244  
 GALT (gut-associated lymphoid tissue),  
 242, 249  
 intestinal DC (dendritic cells), 248–249  
 processes, 243–245  
 treatments  
 diarrhea, 246–247  
*E. coli* infection, 247  
 gastric ulcer, 247  
 for infants, 243
- GLOBAL (Global Landscape On the  
 Bactericidal Activity of Levofloxacin),  
 131
- global standards  
 microbiological testing, 230  
 preservatives/preservation, 139–142
- glycocalyx/capsules, 11–12
- GMPC (Good Manufacturing Practice of  
 Cosmetic Products), 168
- Gram-negative cell envelope, 9–10
- Gram-positive cell wall, 9–10
- green product preservation, 96  
 preservative-free *versus* self-preserving,  
 98–99  
 preservative systems, 97–98
- gut-associated lymphoid tissue (GALT),  
 242, 249
- H**
- HACCP (Hazard Analysis Critical Control  
 Point), 20–21  
 manufacturing plants/processes,  
 171–172, 302
- heat-shock proteins (HSPs), 15–16  
 house (manufacturing plants)  
 microorganisms, 190–191  
 and environmental stresses, 191–193
- house (manufacturing plants)  
 microorganisms  
 cleaning and sanitation practices,  
 196–198  
 survival strategies, 186–187  
 EPS encapsulation, 187–188  
 HSPs (heat-shock proteins),  
 190–193  
 Phoenix phenomenon, 186, 199–206  
 pigments, 188–189  
 siderophores, 189  
 test methods as contributors, 194–196
- HSPs (heat-shock proteins), 15–16  
 house (manufacturing plants)  
 microorganisms, 190–193
- human skin. *See* skin disorders
- hurdle technology, 89–96  
 preservative-free products, 149–150,  
 293
- hyaluronic acid (N-acetylglucosamine and  
 glucuronic acid polymer), 11–12
- I**
- impedance testing, 318–319
- infectious microflora, 211  
*Staphylococcus aureus*, 211, 213–215
- intestinal DC (dendritic cells), 248–249
- inulin, 256
- IRMPs (iron-regulated membrane  
 proteins), 15, 189
- J**
- JCIA (Japan Cosmetic Industry  
 Association), microbiological testing, 320
- JP (Japanese Pharmacopeia), preservative  
 efficacy testing, 28  
 acceptance criteria, 47
- L**
- Lactobacillus* extract, 256–257
- levan (fructose polymer), 11–12
- linear regression method, preservative  
 efficacy testing, 28–31  
 acceptance criteria, 69  
 D-values, 32–40
- LPS (lipopolysaccharide) layer, 9–10,  
 265–268
- M**
- Malassezia*, 224–225
- manufacturing plants/processes  
 CGMPs, 17, 167  
 implementation of, 169–173

- plant and equipment sanitation, 21–22, 170, 196–198
  - contract manufacturers, guidelines, 206–207
  - Cosmetic Good Manufacturing Practice Guidelines update, 173–174
  - equipment sanitation, 21–22, 169–170, 183–184, 196–198, 277–278, 300–301, 303–305
  - GMPCs, 168
  - HACCP, 20–21, 171–172, 302
  - house microorganisms, 185, 300–301
    - cleaning and sanitation practices, 196–198
    - identifying problems, 185–186
    - survival strategies, 186–187, 186–193
    - test methods as contributors, 194–196, 305–306
  - microbial contamination, 20, 171–172
    - controlling, 301–302
    - raw materials, 295, 297–298
    - in raw materials, 174–175
    - in water, 174–175
  - microbiological validation of processes, 182–185, 299–300
  - Phoenix phenomenon, 199
    - avoiding, 205–206
    - finished product testing, 203–204
    - house microorganisms, 186
    - preservative efficacy testing, 202
    - recovery system validation, 204–205
    - substrate-accelerated death, 202
    - suicide response, 201–202
    - VBMC (viable but non-culturable) bacteria, 199–201
  - plant sanitation, 21–22, 170, 183–184, 196–198, 277–278, 300–301, 303–305
  - Pseudomonas*, 263–264, 277–278
    - in finished products, 278–280
  - quality controls, 169
    - laboratories, 172–173
    - production/processes, 170–171
    - sampling and testing, 171
  - raw materials
    - classes, 176–179
    - microbial contamination, 174–175, 295, 297–298
    - microbial specifications, 179–180, 295–297
    - Pseudomonas*, 276–277
    - risk assessment, 175–176, 297–298
    - testing, 175–176
  - water
    - alert or action levels, 299
    - deionized water, 181–182, 298–299
    - microbial contamination, 174–175
    - Pseudomonas*, 276–277
    - Safe Drinking Water Act, 180–182
  - micellar solubilization, 290
  - microbiological test methods, 321–322
    - globalization of, 320
  - microbiology. *See* cosmetic microbiology
  - microorganisms
    - adaptation of, 12–13
    - bacteria growth curve, 2–5
    - growth prevention
      - with decrease of water, 6–7
      - with dry conditions, 6–7
      - by physical or chemical means, 6
    - growth requirements
      - chemical, 2–3
      - physical, 2–3
    - injured but not dead, 7–8
    - survival strategies, 8–16
  - Microsporium*, 230–233
  - monocyte chemotactic protein-1 (MCP-1), 249
- N**
- natural products. *See* organic and natural products
  - NOP (National Organic Program), 159, 293
- O**
- odor, underarm, 24, 221–223
  - oligosaccharides, 256
  - organic and natural products, 323
    - certification, 293
    - ingredients, 159–160
    - microbial limits, 309

**P**

- P. aeruginosa*, 265–266  
 biofilms, 269–270, 275  
 EPSs (exopolysaccharides), 12, 268–269, 275  
 ETA (exotoxin A), 272  
 ETS (exotoxin S), 272  
 flagella, 272  
 LPS (lipopolysaccharide), 265–268  
 pili, 271–272  
 siderophores, 273–274  
 survival strategies, 275
- packaging  
 atypical products, 294  
 critical component, 96  
 preservative efficacy testing, 291  
 preservative-free products, 162–164  
 preservative systems, 79, 83–89
- PCPC (Personal Care Product Council)  
 globalization of microbiological testing, 320  
 preservative efficacy testing, 18, 28, 292  
 acceptance criteria, 47, 69–78
- penetration enhancers in formulas, 121
- peptidoglycan layer, Gram-negative cell envelope, 9–10
- permeabilization synergy, 10
- Personal Care Product Council. *See* PCPC
- personnel, training and responsibilities, 169–170, 304
- Phoenix phenomenon, 199  
 avoiding, 205–206  
 finished product testing, 203–204  
 house microorganisms, 186  
 preservative efficacy testing, 202  
 recovery system validation, 204–205  
 substrate-accelerated death, 202  
 suicide response, 201–202  
 VBMC (viable but non-culturable) bacteria, 199–201
- phospholipid-protein layer, Gram-negative cell envelope, 9–10
- pigmentation of microorganisms, 13–14
- pili, 271–272
- polysaccharides, complex, 11–12, 256
- prebiotics, 256–257
- preservative cocktails, 121
- preservative death time curve, 39–41
- preservative efficacy testing, 286–287  
 acceptance criteria, 47–48, 69–78, 288–290, 322–323  
 errors to avoid, 106–107  
 cosmetic microbiology's future, 315–317  
 kinetics of bacterial death, effect on, 54–63  
 linear regression method, 28–31  
 D-values, 32–40  
 reliability, 49–54  
 methods, 288–290  
 organisms, adapted, 45–46  
 organisms, test  
 errors to avoid, 104–105  
 inoculating with cultures, 44–45  
 selecting, 44
- PCPC (Personal Care Product Council), 18
- preservative concentrations, 287–288
- preservative-free products, 161–162
- preservative system components, synergism of, 63–68
- principles, 40–43
- product isolates, 45
- rechallenge testing, 49–54
- recovery systems, 41–44
- solubilizing agents, 290–291
- test result interpretation, 46–47
- preservative-free products. *See* self-preserving products
- preservatives/preservation  
 antibiotics  
 cross-resistance with, 123–128, 312–315  
 GLOBAL, 131  
 resistance on product development, 131–133  
 resistant microorganism development, 128–131  
 TRUST, 131
- atypical products, 99–104, 293–294
- classes, 114
- cosmetics *versus* foods, 115–117
- drawbacks, 119–120
- dry products, 294–295
- endocrine modulation, 122–123
- formulations

- inaction causes, 136–139
- synergisms with ingredients, 133–136
- frequently used, 113
- global acceptance, 139–142
- hurdle technology, 89–96, 293
- ideal preservatives, characteristics of, 111–112
- microorganism growth prevention
  - with decreasing water, 6–7
  - with dry conditions, 6–7
  - with high/low temperatures, 6
    - by physical or chemical means, 6
- minimum effective concentrations, 117–119
- skin irritation, 120–122
- skin sensitization, 120–122
- preservative systems
  - based on D-values, 78–89
  - green products, 97–98
  - synergism of components, 63–68
- presumptive challenge test, 28
- probiotics
  - AD (atopic dermatitis)
    - hygiene hypotheses, 253
    - oral probiotics, 253–254
    - SCORAD (scoring atopic dermatitis), 253
  - versus* biotherapeutic agents, 241
  - food allergies, 252–253
  - in gastrointestinal tract
    - cross talk between probiotic bacteria and cells, 244
    - diarrhea treatments, 246–247
    - E. coli* infection treatments, 250
    - GALT (gut-associated lymphoid tissue), 242, 249
    - gastric ulcer treatments, 247
    - for infants, 243
    - intestinal DC (dendritic cells), 248–249
    - processes, 243–245
  - safety of, 251–252
  - topical uses, 255–256
  - UV radiation protection, 254–255
  - vaginal infection treatments, 250–251
  - wound treatments, 251
- product release testing
  - CGMPs, 171
  - cosmetic microbiology's future, 317–318
  - microbial limits
    - finished products, 308–309
    - organic and natural products, 309
  - Phoenix phenomenon, 203–204
  - testing processes, 18–20
    - house organism development, 305–306
    - routine testing, 306–308
  - proteins. *See* HSPs; stress proteins
  - pseudomonads, *P. aeruginosa*, 265–266
    - biofilm, 269–270, 275
    - EPSs (exopolysaccharides), 12, 268–269, 275
    - ETA (exotoxin A), 272
    - ETS (exotoxin S), 272
    - flagella, 272
    - LPS (lipopolysaccharide), 265–268
    - pili, 271–272
    - siderophores, 273–274
    - survival strategies, 275
  - Pseudomonas*, 263–264
    - in finished products, 278–280
    - in manufacturing plants, 277–278
    - water/raw material contamination, 276–277

## Q

- quorum sensing/response, 270

## R

- radio-labeled substrates for testing, 319
- resident (normal) microflora, 211
- retention hyperkeratosis, 225

## S

- sanitation, manufacturing equipment and practices, 21–22, 170, 183–184, 196–198, 277–278, 300–301, 303–305
- seborrheic dermatitis, 24, 223–225
- self-preserving products, 147–148. *See also* green product preservation; organic and natural products
  - atypical product preservation, 99–104, 293–294

- formulations, 150–157
    - organic/natural ingredient use, 159–160
  - hurdle technology, 149–150, 293
  - packaging requirements, 162–164
  - preservation principles, 149
    - enzymes, 157–158
    - hurdle technology, 149–150
  - preservative efficacy testing, 161–162
  - versus preservative-free products, 98–99, 147–148
  - Shiga-like toxin producing *E. coli*, 250
  - siderophores, 14–15, 273–274
    - IRMPs (iron-regulated membrane proteins), 273–274
  - skin disorders
    - acne, 24–25, 225–229
    - AD (atopic dermatitis), 229–230
      - hygiene hypotheses, 253
      - oral probiotics, 253–254
      - SCORAD (scoring atopic dermatitis), 253
    - dandruff, 24, 223–225
    - fungal infections (dermatophytoses), 230–233
    - seborrheic dermatitis, 24, 223–225
    - underarm odor, 24, 211–216, 221–223
  - skin microflora
    - CNS (coagulase-negative staphylococci), 211
      - underarm odor, 221–223
    - colonization resistance, 211
    - coryneform bacteria, 217–218
      - underarm odor, 221–223
    - diphtheroid, 217
    - infectious microflora, 211
      - Staphylococcus aureus*, 211, 213–215
      - Malassezia*, 224–225
    - protection of skin, 234
    - resident (normal) microflora, 211
    - Streptococcus pyogenes*, 211, 218–220
    - temporary resident skin flora, 212
    - transient microflora, 211–212
  - spore suspensions, 78
  - Staphylococcus aureus*, 211, 213–215
  - Staphylococcus auricularis*, 215
  - Staphylococcus capitis*, 215, 216
  - Staphylococcus caprae*, 215
  - Staphylococcus cohinii*, 215
  - Staphylococcus epidermidis*, 211, 215, 216
  - Staphylococcus haemolyticus*, 215, 216
  - Staphylococcus hominis*, 211, 215, 216
  - Staphylococcus ischleiferi*, 215
  - Staphylococcus lugdunensis*, 215, 216
  - Staphylococcus lugdunensis*, 215
  - Staphylococcus saccharolyticus*, 215
  - Staphylococcus saprophyticus*, 215
  - Staphylococcus simulans*, 215
  - Staphylococcus warneri*, 215, 216
  - Staphylococcus xylosus*, 215
  - stingers/nonstingers, 120
  - Streptococcus pyogenes*, 211, 218–220
  - stress proteins, 15–16
  - survival curve slope method, 67
  - survivor curve, 31–34
- T**
- teichoic acid, 9
  - temporary resident skin flora, 212
  - transient microflora, 211–212
  - Trichophyton*, 230–233
  - TRUST (Tracking Resistance in the United States Today), 131
  - twitching motility, 271–272
- U**
- underarm odor, 24, 221–223
  - United States, Food and Drug Administration. *See* FDA
  - USP (United States Pharmacopoeia)
    - acceptance criteria, 47, 69–78
    - microbiological testing, 321
    - preservative efficacy testing, 18, 28, 292
  - UV radiation protection, probiotics, 254–255
- V**
- vaginal infection treatments, 250–251
  - VBMC (viable but non-culturable)
    - bacteria, 199–201
  - verotoxin-producing *E. coli*, 250

**W**

WHO (World Health Organization),  
probiotics, 241  
wound treatments, 251